Original Article

You have full text access to this OnlineOpen article

Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL

The “PSA negative” patients

  1. Alison J. Birtle B.Sc., M.D.1,†,*,
  2. Alex Freeman M.D., Ph.D.2,
  3. John R. W. Masters Ph.D.1,
  4. Heather A. Payne M.D.3,
  5. Stephen J. Harland M.D.3,
  6. Contributors to the BAUS Section of Oncology Cancer Registry‡

Article first published online: 20 OCT 2003

DOI: 10.1002/cncr.11821

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2362–2367, 1 December 2003

Additional Information

How to Cite

Birtle, A. J., Freeman, A., Masters, J. R. W., Payne, H. A., Harland, S. J. and Contributors to the BAUS Section of Oncology Cancer Registry (2003), Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL. Cancer, 98: 2362–2367. doi: 10.1002/cncr.11821

Author Information

  1. 1

    Prostate Cancer Research Center, The Institute of Urology, University College London, London, United Kingdom

  2. 2

    Department of Histopathology, University College London, London, United Kingdom

  3. 3

    The Meyerstein Institute of Oncology, The Middlesex Hospital, London, United Kingdom

  1. †

    Fax: (011) 44-2076799296

  2. ‡

    All authors are contributors to the BAUS Section of Oncology Cancer Registry Institutions.

*Prostate Cancer Research Center, The Institute of Urology, Third Floor Charles Bell House, Riding House Street, London W1W 7EJ, UK

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 20 OCT 2003
  3. Manuscript Accepted: 1 SEP 2003
  4. Manuscript Revised: 25 AUG 2003
  5. Manuscript Received: 11 JUN 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (108K)

REFERENCES

  • 1
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909–916.
  • 2
    Pantelides ML, Bowman SP, George NJ. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol. 1992; 70: 299–303.
  • 3
    Daver A, Soret JY, Coblentz Y, Allain YM, Cellier P, Chauveau P. The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol. 1988; 11 (Suppl 2): S53–S60.
  • 4
    Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am. 1993; 20: 705–771.
  • 5
    Yamamoto S, Ito T, Akiyama A, Aizawa T, Miki M, Tachibana M. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL. Int J Urol. 2001; 8: 374–379.
    Direct Link:
  • 6
    Oommen R, Geethanjali FS, Gopalakrishnan G, et al. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate. Br J Radiol. 1994; 67: 469–471.
  • 7
    Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol. 1998; 33: 376–381.
  • 8
    Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990; 143: 747–752.
  • 9
    Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen-independent prostate cancer. Eur Urol. 2000; 38: 250–254.
  • 10
    Hall R, Hedlund PO, Ackermann R, et al. Evaluation and follow-up of patients with N1–3 M0 or NXM1 prostate cancer in Phase III trials. Urology. 1997; 49: 39–45.
  • 11
    Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a Phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993; 42: 119–129.
  • 12
    Ventafridda V, Saita L, Ripamonti C, De Conno F. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React. 1985; 7: 93–96.
  • 13
    BAUS Section of Oncology. Analysis of minimum data set for urological cancers, January 31 to December 31, 2001. British Association of Urological Surgeons, 2001.
  • 14
    Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol. 1995; 75: 778–781.
    Direct Link:
  • 15
    Gaffney EF, O'Sullivan SN, O'Brien A. A major solid undifferentiated carcinoma pattern correlates with tumour progression in locally advanced prostatic carcinoma. Histopathology. 1992; 21: 249–255.
    Direct Link:
  • 16
    Kageyama Y, Kihara K, Kamata S, et al. Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer. Hinyokika Kiyo. 1996; 42: 197–199.
  • 17
    Saad F, Bertrand P, Paquin JM, Peloquin F. Usefulness of prostate-specific antigen in the diagnosis of lymphatic metastases in cancer of the prostate. Ann Chir. 1995; 49: 680–684.
  • 18
    Smith DC, Tucker JA, Trump DL. Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol. 1992; 10: 499–505.
  • 19
    Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998; 33: 1036–1042.
  • 20
    Labrie F, Dupont A, Giguere M, et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol. 1988; 61: 341–346.
    Direct Link:
  • 21
    Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997; 15: 382–388.
  • 22
    Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in Phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994; 12: 1868–1875.
  • 23
    Brausi M, Jones WG, Fossa SD, et al. A high dose epirubicin is effective in measurable metastatic prostate cancer: a Phase II study of the EORTC Genitourinary Group. Eur J Cancer. 1995; 31A: 1622–1626.
  • 24
    Chao D, von Schlippe M, Harland SJ. A Phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. Eur J Cancer. 1997; 33: 1230–1233.
  • 25
    Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol. 2002; 20: 31–35.
View Full Article (HTML) Get PDF (108K)